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We used RNA interference, which causes sequence-specific
degradation of target mRNAs to suppress the production of
parathyroid hormone by cells of patients with secondary
hyperparathyroidism in vitro and in vivo. Transfection of
small interfering RNA (siRNA) against human parathyroid
hormone into monolayers of parathyroid cells cultured from
these patients caused a dose-dependent decrease of
secretion and mRNA levels with 80% or more suppression
using 40 nM siRNA. Parathyroid cells cultured on non-
adherent plastic produced spheroid cell aggregates which
secreted parathyroid hormone for more than 150 days.
Transfection of these spheroids with 50 nM targeted siRNA
decreased parathyroid hormone production to 20% of the
control level, with half of them being suppressed for 50 days.
When parathyroid cells were transplanted into the livers of
athymic nude mice, plasma human parathyroid hormone
rose to 100–300 pg/ml within one month and remained at
about this level for at least 39 days. Systemic delivery of
hormone-targeted siRNA into these mice caused a dose-
dependent suppression of circulating human parathyroid
hormone for at least one month, with a maximum 80%
suppression achieved by 80 lg of siRNA. Our study shows
that hormone secretion by parathyroid cells of patients with
secondary hyperparathyriodism can be suppressed both
in vitro and in vivo by targeted siRNAs.
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Secondary hyperparathyroidism (2HPT) is one of the most
important complications of chronic kidney disease (CKD). In
CKD, parathyroid hormone (PTH) secretion is stimulated by
hypocalcemia, phosphate retention, and reduced levels of
activated vitamin D3 (1,25-D).1 When 2HPT is left
untreated, parathyroid (PT) hyperplasia ensues and pre-
cipitates hypercalcemia and hyperphosphatemia, leading to
ectopic calcification and vascular sclerosis, which determine
the prognosis of dialysis patients.2–4 Although 1,25-D pulse
therapy is effective for 2HPT, hyperplastic PT cells gradually
develop resistance to 1,25-D. Once PT cells acquire resistance
to 1,25-D, the only treatment of choice is parathyroidectomy
or necrotic destruction of the PT glands by percutaneous
ethanol injection. However, when surgical interventions are
selected, postoperative PTH control is difficult, and PT
autograft is associated with the risk of 2HPT relapse.
Vitamin D3 resistance in 2HPT involves multiple
mechanisms that compromise the regulation of PTH
production by vitamin D3 and calcium. Vitamin D3 receptor
(VDR) levels are decreased in the PT glands of dialysis
patients and animal models of renal failure.5–9 The binding of
normal rat VDRs to vitamin D responsive elements can be
inhibited by uremic toxins,10 and VDRs from renal failure
rats have reduced ability to bind vitamin D responsive
elements.10,11 Moreover, retinoid X receptor levels are
decreased in rats with renal failure,11 further impairing
VDR activity, because VDR exerts its action in the form of
heterodimer with retinoid X receptor.12 As 1,25-D is
responsible for upregulation of VDR, a vicious cycle begins
in 2HPT and perpetuates insufficient 1,25-D actions.
Furthermore, calcium sensing receptors (CaR) levels are
decreased in hyperplastic PT glands of patients with uremic
hyperparathyroidism,13 which, in part, accounts for the
elevated setpoint of calcium concentration for inhibiting
PTH secretion in 2HPT 14 and may affect the action of type II
calcimimetics that suppress PTH secretion via the allosteric
modulation of CaR.15
RNA interference (RNAi) is a mechanism of cell that
inhibits gene expression by causing the degradation of
specific mRNAs or hindering the transcription of specific
genes.16 Double-stranded small interfering RNAs (siRNAs)
play a key role in activating the RNAi machinery that
specifically degrades mRNAs with sequences complementary
to siRNA.16 Discoveries that the RNAi machinery can be
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 2 May 2008; revised 9 September 2008; accepted 16
September 2008; published online 26 November 2008
Correspondence: Akira Saito, Division of Nephrology and Metabolism,
Department of Medicine, Tokai University School of Medicine, 143
Simokasuya, Isehara, Kanagawa 259-1193, Japan.
E-mail: asait@is.icc.u-tokai.ac.jp
490 Kidney International (2009) 75, 490–498
activated by siRNAs in cultured mammalian cells 17 and
mice 18 provided impetus to exploring RNAi for therapeutic
purposes. Because of the mechanism of action, RNAi would
provide a specific therapeutic means that can circumvent
vitamin D3 resistance and control PTH production in 2HPT
complicating CKD.
In this study, we examined both in vitro and in vivo the
potential use of RNAi to suppress PTH production in PT
cells of 2HPT patients. First, we used monolayer cultures of
PT cells from 2HPT patients to evaluate short-term effects of
siRNAs targeted to human PTH mRNA. Then, we established
a spheroid culture of PT cells to examine long-term effects of
siRNAs. Finally, we transplanted PT cells into the liver of
athymic nude mice and evaluated in vivo effects of siRNAs.
RESULTS
Effects of siRNAs in monolayer cultures of PT cells
PT cells were dissociated from PT glands of 2HPT patients
and, after removal of fibroblasts, incubated on collagen type
I-coated plates. Immunostaining showed that 90% or more
cells were positive for PTH (Figure 1). Within a few weeks of
culture, PTH-positive cells were found in polygonal clusters
surrounded by overgrowing fibroblasts (Figure 1).
PTH secretion in monolayer PT cells reached a peak after
approximately 1 week of culture, decreased afterwards, and
became marginal by 3 weeks of culture (Figure 2a). The
observed single-peak changes in PTH secretion were shared
by all specimens, whereas the amount of secreted PTH varied
from one specimen to another. Transfection of anti-PTH
siRNA caused dose-dependent suppression of PTH secretion
(Figure 2a). More than 75% of the peak PTH secretion was
suppressed at a final concentration of 40 nM (86.0±3.6%
suppression; N¼ 6). Negative control siRNA had no
appreciable effects at the same concentration. PTH mRNA
levels were determined by real-time PCR after transfection of
50 nM siRNA (Figure 2b). Following transfection of negative
control siRNA, PTH mRNA levels reached a peak on day 1
and declined. In contrast, PTH mRNA levels in the anti-PTH
siRNA-transfected cultures decreased significantly on day 1
after transfection (86.9±1.9% suppression; Po0.05 vs
control siRNA; N¼ 3) and remained significantly lower than
those in the control cultures. Three siRNAs targeting
different parts of PTH mRNA showed similar suppressing
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Figure 1 | Monolayer cultures of human PT cells. PT cells were
depleted of fibroblasts by processing with anti-fibroblast
antibody-conjugated magnetic beads, inoculated at 5 105 cells/
well onto adherent 24-well plates. On days 1 and 14 of culture, the
cells were examined by phase contrast microscopy (Phase
contrast) or immunostaining and fluorescence microscopy for
parathyroid hormone (PTH).
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Figure 2 | Effect of siRNA on PTH secretion and PTH mRNA
levels in monolayer cultures of human PT cells. PT cells were
cultured on adherent plates as described in the legend to
Figure 1. When the cells were a 70–90% confluent monolayer, they
were either left nontransfected or transfected with negative
control siRNA or anti-PTH siRNA. (a) PTH secretion. The amount of
intact human PTH secreted in 24 h was measured at the indicated
time points in nontransfected cells and cells transfected with
negative control siRNA at 50 nM or anti-PTH siRNA at 10 nM, 20 nM
or 40 nM. Shown are the mean values of a representative of six
experiments performed in duplicate. (b) PTH mRNA. Total RNA
was purified at the indicated time points from cells transfected
with 50 nM of negative control siRNA or anti-PTH siRNA. Real-time
PCR was performed for PTH mRNA and 18S rRNA, and results were
expressed in a ratio of PTH mRNA to 18S rRNA. The values for day
0 were obtained from cells harvested before transfection. Values
are the mean±s.d. of triplicate of a representative of three
experiments. *Po0.05 between negative control siRNA and anti-
PTH siRNA.
Kidney International (2009) 75, 490–498 491
G Kanai et al.: Suppression of PTH production by RNAi o r i g i n a l a r t i c l e
effects (data not shown), excluding the possibility of off-
target effects.
Long-term spheroid culture of functional PT cells
To evaluate long-term effects of siRNAs, we attempted three-
dimensional culture. When PT cells were cultured on round-
bottom nonadherent 96-well plates, the cells coalesced to
each other and, within a few days, formed an aggregate, or
‘spheroid.’ Spheroid formation was highly reproducible when
PT cells were plated at 5 104 to 1 106 cells/well. Spheroids
were also formed at 1 104 cells/well or less; however,
spheroids shrank and PTH secretion ceased rapidly. Spheroid
formation was inconsistent at 1 107 cells/well or higher
(data not shown).
The spheroids had a diameter of 100–500 mm and were not
a simple cell cluster (Figure 3). Each spheroid consisted of
compact cell masses separated by acellular spaces. Some
spheroids were covered by a layer of cells. Immunostaining
revealed that PTH production occurred in the cell masses,
but not in the surface cell layer (Figure 3). No proliferation of
fibroblasts was observed on the surface of nonadherent
plates.
In PT cell spheroids, PTH secretion peaked within 2–3
weeks of culture, followed by a period of steady secretion that
continued for about 2 months, and began to decline (Figure 4a).
This pattern of PTH secretion was consistent among different
specimens, whereas the amount of secreted PTH varied with
the specimen and the number of cells inoculated per well.
The size of spheroid did not change during the steady
secretion period; however, it began to decrease as PTH
secretion dwindled. Cells positive for Ki-67, a marker for cell
proliferation, were hardly seen in the spheroids throughout
the culture period (Figure 4b). Likewise, cells expressing
active caspase-3, a marker for apoptosis, were very few during
the steady period; however, they increased later as the
spheroid size and PTH secretion decreased (Figure 4b).
To determine the functionality of PT cells in spheroid
culture, we examined the expression of CaR and the
responsiveness to changes in extracellular calcium concentra-
tion (Figure 5). Immunostaining demonstrated that PT cells
in spheroids continued to express CaR on cell membranes
throughout the culture period (Figure 5a). When PT cell
spheroids were incubated in a low-calcium medium
(0.5 mM), PTH secretion was increased, whereas the secretion
was decreased on incubation in a high-calcium medium
(3.0 mM), as compared with that seen in the standard
medium containing 1.25 mM calcium (Figure 5b).
Effects of siRNAs in PT cell spheroids
To determine the effect of siRNAs in PT cell spheroids,
monolayer PT cells were transfected with siRNAs and
replated onto nonadherent plates. Similar to nontransfected
PT cells, the cells transfected with negative control siRNA
formed spheroids within a few days of replating and secreted
PTH in a pattern characterized by a peak occurring within
2–3 weeks after replating and a subsequent steady secretion
period (Figure 6a). The anti-PTH siRNA-transfected cells
also formed spheroids within a few days after replating.
However, the peak of secretion was largely suppressed
(85.9±5.7% suppression; N¼ 8) and the period of steady
secretion was replaced by a gradual increase, with PTH
secretion reaching the control levels by the end of 2–3 months
of culture (Figure 6a).
Immunostaining revealed that the amount of PTH-
secreting cells changed in parallel with the PTH secretion
level (Figure 6b). In PT cell spheroids transfected with
negative control siRNA, PTH immunoreactivity was intense
and widely distributed at the peak of secretion (day 16 in
Figure 6b), became less intense during the steady secretion
(day 42) and increased its intensity whereas becoming less
extensive during the steady secretion period (day 82).
Changes in PTH immunoreactivity also overlapped those in
PTH secretion in anti-PTH siRNA-transfected cells. Early
after spheroid formation, PTH immunoreactivity was
scattered (day 16 in Figure 6b); it became very weak when
the secretion was suppressed (day 42), and became intense
and widely distributed when PTH secretion increased toward
the control levels (day 82).
Frequencies of cell proliferation and apoptosis were
similar between the negative control siRNA and anti-PTH
Phase contrast PTH H & E
Figure 3 | Spheroid cultures of human PT cells. PT cells were depleted of fibroblasts as described in the legend to Figure 1 and inoculated
at 2.4 105 cells/well onto nonadherent 96-well plates. On day 42 of culture, PT cell spheroids were examined by phase contract
microscopy (Phase contrast), immunostaining and fluorescence microscopy for parathyroid hormone (PTH), or hematoxylin and eosin
staining (H&E). Original magnification  100. Scale bar represents 100 mm.
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siRNA-transfected spheroids (Figure 7). Thus, the observed
suppression of PTH secretion reflected the specific effect of
siRNA on PTH secretion.
Effects of siRNAs on human PT cells transplanted into
athymic nude mice
To evaluate the effects of siRNAs in an in vivo setting,
2.7 106 PT cells were transplanted into the liver of athymic
nude mice. After 1 month, the plasma concentrations of
intact human PTH were 100–300 pg/ml and remained at
these levels throughout the 39 days of experimental period
(Figure 8). The PTH secretion level differed from specimen to
specimen. In the absence of transplantation, PTH concentra-
tions remained below the lower limit of the assay range
(15 pg/ml). siRNAs were introduced into the mice via the tail
vein by hydrodynamic method. Negative control siRNA had
no appreciable effect on the plasma human PTH concentra-
tions until the end of experimental period (a maximum of
13.7±6.5% suppression on day 2 after transfection; N¼ 4;
Figure 8). In contrast, anti-PTH siRNA caused dose-
dependent suppression of human PTH secretion. On day 8
after siRNA introduction, plasma PTH levels were decreased
by 56.8±6.8% (N¼ 4), 70.1±10.7% (N¼ 3), and
78.5±0.6% (N¼ 3) of the pre-introduction levels with 40,
80, and 120 mg of siRNA, respectively. The onset of
suppression was similar with different doses of siRNA,
occurring on day 2 after siRNA introduction. The duration of
suppression varied with the dose of siRNA, with 60% or
greater suppression continuing for more than 2 weeks with
120 mg of siRNA.
DISCUSSION
In this study, we explored in vitro and in vivo the use of RNAi
to suppress PTH production by PT cells from advanced
2HPT patients. First, we examined the in vitro effects of
siRNAs using monolayer PT cell cultures. Results showed that
anti-PTH siRNAs induced dose-dependent suppression of
PTH secretion and PTH mRNA levels, demonstrating that
anti-PTH siRNAs triggered the RNAi machinery in PT cells
of advanced 2HPT patients, leading to the degradation of
PTH mRNA and the suppression of PTH production.
PTH production in monolayer PT cells dwindled after
15–20 days of culture, coinciding with robust fibroblast
proliferation. Primary cultures of dialysis patients’ PT cells
have been used as an in vitro model of 2HPT, and response of
PTH production to calcium, phosphate or 1,25-D has been
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Figure 4 | PTH secretion, cell proliferation and apoptosis in human PT cell spheroids. PT cell spheroids were prepared as described in
the legend to Figure 3. (a) PTH secretion. Intact human PTH secreted in 24 h was determined at the indicated time points by ELISA. Values
are the mean±s.d. of four representative samples of eight experiments. (b) Cell proliferation and apoptosis. On days 16, 42, and 82 of
culture, the immunoreactivities of Ki-67 (as a marker of cell proliferation) and active caspase-3 (as a marker of apoptosis) were examined by
fluorescence microscopy in sections of spheroids. Original magnification  100. Scale bar represents 100 mm.
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investigated.19,20 Methods have been reported for long-term
culture of human PT cells;19–21 however, our attempts with
these methods were unsuccessful primarily because of
overwhelming fibroblast proliferation. Neither D-valine-sub-
stituted medium22 nor removal of fibroblasts with anti-
fibroblast antibody-conjugated magnetic beads was suffi-
ciently effective.
For long-term culture of functioning PT cells, we resorted
to three-dimensional culture or ‘spheroid culture.’ When PT
cells from 2HPT patients were plated on nonadherent plates,
they formed ‘spheroids’ and continued to secrete PTH for 3
months or more. No fibroblast proliferation was observed on
the surface of nonadherent plates. The PT cell spheroids
consisted of compact cell masses separated by acellular,
substrate-filled spaces, an architecture similar to that of
‘organoids’ or ‘pseudoglands’ formed by bovine PT cells
cultured in roller bottles23 or in collagen matrix.24 PTH
production occurred in compact cell masses, but not in a
layer of cells observed on the surface of some spheroids.
These findings suggest that whereas nonadherent plates
inhibited proliferation of anchorage-dependent fibroblasts,
remaining fibroblasts were sorted out of PT cell aggregates,
formed a layer on the surface of spheroid and ceased
proliferation due to contact inhibition. The relationship
between fibroblasts and PT cells in spheroid is reminiscent of
that observed between the capsule and glandular cells in PT
hyperplasia.23,24
In general, PT cells rapidly lose functionality in monolayer
cultures25,26 although two studies reported that PT cells from
2HPT patients retained functionality for up to 5 months19 or
60 days.20 Besides the fibroblast overgrowth, the short-lived
functionality of monolayer PT cells has been ascribed to their
proliferation-associated dedifferentiation and insufficient
cell-to-cell contact. Earlier studies associated avid prolifera-
tion of PT cells with decreased functionality.27–29 In fact,
inhibition of proliferation was found to help monolayer PT
cells retain differentiated function.24,30 A study reported that
PTH secretion was more active when PT cells were plated at a
high density to allow cell-to-cell contact and, possibly,
contact inhibition.31 In this regard, multicellular aggregates
of PT cells obtained by roller bottle culture 23 or in collagen
matrix24 were both characterized by negligible proliferation
and high levels of cell-to-cell contact, indicating the
importance of three-dimensional tissue-like architecture.
Our spheroid culture of PT cells was benefited from these
features: PT cells were organized in three-dimensional
configuration, provided with sufficient cell-to-cell contact,
and exhibited virtually no proliferative activity. Thus, PT cells
in spheroids continued to express CaR and retained the
responsiveness to extracellular calcium concentration for 2–3
months of experimental period.
The PT cell spheroids had a peak PTH secretion after 2–3
weeks of culture and entered a period of steady secretion that
lasted for at least 3 months. No substantial cell proliferation
was observed throughout the culture period. Apoptosis was
few until the later stage of steady secretion when the
spheroids began to shrink and showed decreased PTH
secretion. These findings suggest that the observed changes
in PTH secretion mirrored those in the secretion capacity of
individual PT cells until the later stage of steady secretion. In
2HPT, PT cells are exposed to stimuli for PTH secretion,
including decreased 1,25-D and calcium and increased
phosphate.1 Two studies claimed success in long-term
monolayer cultures of functional human PT cells and
attributed the success, in part, to the choice of medium: a
low-calcium (0.09 mM) medium20 and a phosphate-rich
(5.6 mM) medium.19 We used a medium containing moderate
concentrations of calcium (1.25 mM) and phosphate
(2.6 mM), which would be less stimulating to PT cells than
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Figure 5 | Responsiveness of human PT cell spheroids to
calcium. PT cell spheroids were prepared as described in the
legend to Figure 3. (a) Calcium sensing receptors (CaR) in
spheroids. On days 23, 44, 78, and 121 of culture, CaR expression
was examined by immunostaining and fluorescence microscopy
in sections of spheroids. Original magnification  400. Scale bar
represents 50mm. (b) Calcium regulation of PTH secretion. After 1,
5, 9, and 13 weeks of culture, spheroids prepared from the same
PT glands were incubated simultaneously in a medium containing
either a low (0.5 mM), standard (1.25 mM), or high (3.0 mM)
concentration of ionized calcium, and intact human PTH secreted
in 24 h was determined by ELISA. Values of secreted PTH are
presented in percentage of that in the medium containing
1.25 mM calcium. Values are the mean±s.d. of more than nine
separate spheroid cultures per condition. *Po0.05 between high
and low calcium media.
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the above two media or the in vivo environment of 2HPT
patients. Thus, it is possible that the observed peak and
steady state of PTH secretion represented, respectively, a
stimulated state and a baseline-like state of PT cells, with the
stimulated state persisting until the cells adjusted to a new
environment. In our monolayer cultures, the stimulated state
was truncated and the baseline-like state was barely
recognizable probably because of insufficient cell-to-cell
contact and fibroblast overgrowth.
In spheroid cultures, anti-PTH siRNA suppressed PTH
production by 90% or more for approximately 1 month, and
50% or greater suppression persisted for at least 50 days. We
chose to transfect monolayer PT cells, then, transfer them to
nonadherent plates, because transfecting PT cell spheroids
resulted in poor suppression of PTH secretion or cell damage
at higher concentrations of siRNA. The observed long-term
effect of anti-PTH siRNA is partly attributable to the
chemical modifications of siRNAs. It can also be related to
the characteristics of PT cells. PT cells in spheroids exhibited
virtually no proliferative activity, which may have minimized
cell division-associated dilution of transfected siRNA.
Furthermore, PT cells of 2HPT patients are characterized
by decreased nuclease activities that cause PTH mRNA
accumulation and PTH overproduction32 and would
prolong half-lives of siRNAs. These characteristics of PT
cells of 2HPT patients are advantageous to clinical applica-
tion of siRNAs.
Results showed that anti-PTH siRNAs were effective for
gene knockdown of PTH in PT cells in vitro. However,
properties of cells can change when transferred to an in vitro
culture environment. Therefore, we transplanted human PT
cells into the liver of nude mice immediately after their
isolation to preserve their in vivo state. We chose the liver for
transplantation because systemically introduced nucleic acids
are delivered most efficiently to hepatocytes with the
hydrodynamic method.33 After 1 month of transplantation,
intact human PTH was found in high concentrations in the
blood of the recipient mice and retained these levels for at
least 1 month, indicating that the transplanted human PT
cells maintained their secretion function for at least 2
months. These are in line with Roussanne et al.19 who
subcutaneously transplanted PT cells of 2HPT patients into
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Figure 6 | Effect of siRNA on PTH secretion and PTH immunoreactivity in spheroid cultures of human PT cells. PT cells were prepared
as described in the legend to Figure 2, transfected with 50 nM of negative control siRNA or anti-PTH siRNA, and replated at 1.7 105 cells/
well onto nonadherent 96-well plates for spheroid formation. (a) PTH secretion. The amount of PTH secreted in 24 h was measured at the
indicated time points. Values are the mean±s.d. of triplicate of a representative of eight experiments. (b) PTH immunoreactivity. On days
16, 42, and 82 of culture, PTH immunoreactivity was examined by fluorescence microscopy in sections of spheroids. Original magnification
 100. Scale bar represents 100 mm.
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nude mice and found that intact human PTH concentrations
reached 41000 pg/ml and retained a mean level of 390 pg/ml
9 months after transplantation. Hydrodynamic delivery of
anti-PTH siRNA caused dose-dependent suppression of PTH
secretion. A maximum of 80% suppression was achieved by
80 mg of siRNA, and some 60% suppression continued for up
to 1 month with 120 mg. These findings provided evidence
that the systemically delivered siRNA survived in the
circulation, reached the cytoplasm of the transplanted human
PT cells and efficiently suppressed PTH secretion. Thus, anti-
PTH siRNAs were effective in suppressing PTH production
in vivo, and the effect persisted for 6 weeks or longer.
This study demonstrated the applicability of siRNA-
mediated RNAi activation to the therapy of 2HPT. We are
currently developing a method in which gels containing
siRNA and transfection reagents are injected into the inside
and surroundings of PT glands in a manner similar to
percutaneous ethanol injection therapy. Use of recently
developed chemical modifications of siRNAs, such as
addition of cholesterols to siRNAs to improve cell membrane
penetration,34 will help enhance the efficiency of transfection
and prolong the half-lives of siRNAs. RNAi-based approach
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Anti-PTH siRNA
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Day 42 Day 82
Figure 7 | Effects of siRNA on cell proliferation and apoptosis in spheroid cultures of human PT cells. PT cells were prepared,
transfected with 50 nM of negative control siRNA or anti-PTH siRNA, and replated for spheroid formation as described in the legend to
Figure 6. On days 16, 42, and 82 of culture, Ki-67 and active caspase-3 immunoreactivities were examined by fluorescence microscopy in
sections of spheroids. Original magnification  100. Scale bar represents 100 mm.
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Figure 8 | Effect of siRNA on PTH secretion in human PT cells
transplanted into athymic nude mice. PT cells were
transplanted into the liver of athymic nude mice at 2.7 106 cells
per mouse. After 1 month, 40, 80, or 120 mg of anti-PTH siRNA or
120mg of negative control siRNA was introduced into the mice via
the tail vein by hydrodynamic method. Intact human PTH
concentration in the plasma was measured at the indicated time
points after the siRNA introduction. PTH concentration is
presented in a percentage of that immediately before siRNA
introduction (day 0). Data are from a representative of at least
three mice for each condition. PTH concentrations in intact nude
mice without human PT cell transplants were below the detection
range of ELISA for intact human PTH.
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would reduce the need for calcimimetics and/or vitamin D3
supplementation and allow easier postoperative PTH control.
MATERIALS AND METHODS
This study protocol was approved by the Institutional Review Board
of Tokai University School of Medicine. Human materials were used
under the informed consent of the patients.
Preparation and monolayer culture of human PT cells
The PT glands were removed from 17 CKD patients who were
diagnosed with advanced 2HPT and indicated for surgical interven-
tions. The glands from different patients were handled separately,
and PT cells from different patients were not mixed. The glands were
minced, washed with DMEM/Ham’s F12 medium (Wako, Osaka,
Japan) supplemented with 5% fetal calf serum and digested at 37 1C
for 30 min with 0.2% collagenase type II (Worthington, Lakewood,
NJ, USA). PT cells were dispersed by pipetting and filtered through a
70mm mesh. After repeated washing, red blood cells were removed
by a lysing solution (VersaLyse; Beckman Coulter, Fullerton, CA,
USA). PT cells were washed and resuspended in DMEM/
F12þGlutaMax-1 medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% fetal calf serum, 50 U/ml penicillin and 50mg/ml
streptomycin and incubated on tissue culture-treated plates in a
humidified atmosphere of 95% air/5% CO2 at 37 1C. On the
following day, adherent cells were harvested by trypsinization and
resuspended at a density of 1 107 cells/80 ml in phosphate-buffered
saline without calcium and magnesium (PBS) containing 0.5%
bovine serum albumin, mixed with 20 ml of anti-fibroblast antibody-
conjugated magnetic microbeads suspension (Anti-Fibroblast
MicroBeads; Miltenyi Biotec, Bergisch Gladbach, Germany) and
incubated at room temperature for 30 min. Cells were washed and
loaded onto a magnetic column of auto-MACS cell sorting system
(Miltenyi Biotec). Fibroblast-depleted cells were collected, resus-
pended in DMEM/F12þGlutaMax-1 medium supplemented as
above, inoculated at a density of 5 105 cells/well onto collagen type
I-coated 24-well plates (Becton Dickinson Labware, Franklin, NJ,
USA) and incubated in a humidified atmosphere of 95% air/5%
CO2 at 37 1C. Medium was renewed every other day.
In vitro siRNA transfection
siRNAs targeted to human PTH mRNA (anti-PTH siRNAs; PTH-
HSS108784, PTH-HSS108785, and PTH-HSS108786 of Stealth
RNAi) and negative control siRNA (Low GC) were purchased from
Invitrogen (Carlsbad, CA, USA). Fibroblast-depleted PT cells were
incubated for a few hours at 5 105 cells/well on collagen type
I-coated 24-well plates until 70–90% confluency was achieved. Then,
siRNA mixed with a transfection reagent (RNAiMax; Invitrogen) at
a ratio of 6 pmol to 1 ml was added to the cultures. Medium was
changed after overnight incubation in a humidified atmosphere of
95% air/5% CO2 at 37 1C.
Quantitative real-time PCR
Total RNA was extracted using RNAqueous-4PCR kit (Applied
Biosystems, Foster City, CA, USA) and converted to cDNA using
SuperScript III First-Strand Synthesis System (Invitrogen). Resulting
cDNA solution was diluted 60-, 120-, 240-, and 480-fold with distilled
water and used as templates. Reaction mixture was prepared as
described in the instruction manual of a kit (TaqMan Gene
Expression Assays; Applied Biosystems) containing primers and
probes for intact human PTH (Assay ID: Hs00174888_m1) and
eukaryotic 18S rRNA used as an internal control. PCR was performed
on an ABI PRISM 7700 Sequence Detector (Applied Biosystems).
Data were analyzed by the comparative Ct method, and the amount of
PTH mRNA was expressed relative to that of 18S rRNA.
Spheroid culture of human PT cells
Fibroblast-depleted PT cells were suspended in DMEM/
F12þGlutaMax-1 medium supplemented as above and plated at
1 104 to 1 106 cells/well onto nonadherent round-bottom 96-
well plates (SUMILON Celltight Spheroid 96U; Sumitomo Bakelite,
Tokyo, Japan). The cells were incubated in a humidified atmosphere
of 95% air/5% CO2 at 37 1C. Medium was renewed every other day.
To examine the effect of siRNAs in spheroids, monolayer PT cells
were transfected with siRNA as described above and replated on
nonadherent round-bottom 96-well plates for spheroid formation.
In some experiments, PT cell spheroids were incubated in a medium
containing either 0.5 mM or 3.0 mM calcium, as opposed to 1.25 mM
calcium in the standard medium. These media were prepared by
adding CaCl2 to calcium-free DMEM/F12þGlutaMax-1 medium
(Gibco Invitrogen). Concentration of ionized calcium was deter-
mined using a calcium-selective electrode after the medium was
completed with fetal calf serum and antibiotics as described above.
Immunohistochemistry
PT cell spheroids were fixed with 4% paraformaldehyde and frozen
in OCT compound (Sakura Finetechnical, Tokyo, Japan). Ten-
micrometer thick Sections of 10 mm were dried and rinsed with PBS
and blocked with 1% blocking reagent (Invitrogen). Primary
antibodies included anti-PTH antibody (sc-9678; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti-Ki-67 antibody (sc-
23900; Santa Cruz Biotechnology), anti-active caspase-3 antibody
(Promega, Madison, WI, USA) and anti-calcium-sensing receptor
antibody (sc-32181; Santa Cruz Biotechnology). Bound antibodies
were visualized using Tyramid Signal Amplification Kit (Invitrogen)
and observed under the fluorescent microscope.
Human PT cell transplantation in athymic nude mice
PT cells were suspended in PBS, and 50ml of cell suspension
containing 2.7 106 cells was injected into the liver of 4- to 5-week-
old athymic nude mice (Nihon CLEA, Tokyo, Japan) under
anesthesia. After 1 month, blood was sampled from the tail vein
for quantification of intact human PTH, and siRNA was introduced
into the recipient mice. siRNA was resolved in 3.1 ml of a
hydrodynamic injection solution (TransIT-QR Hydrodynamic De-
livery Solution; Mirus, Madison, WI, USA) and injected into the tail
vein within 4–7 s. The plasma concentration of intact human PTH
was measured at the time points described in the figure legends.
PTH determination
Intact human PTH was quantified by ELISA (hPTH-EASIA;
BioSource Europe SA, Nivelles, Belgium). For cultured PT cells,
medium was renewed 24 h before sampling. Samples were
centrifuged, and supernatants were diluted with a fresh medium
to adjust the PTH concentration within the assay range (15–1,
200 pg/ml). All samples and standards were duplicated, and average
values were used for analysis.
Statistical analysis
Data are shown as mean±s.d. Differences were analyzed by two-
tailed Student’s t-tests. A P-value of o0.05 was considered
statistically significant.
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